Clinical Trial Detail

NCT ID NCT03915951
Title An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Array BioPharma
Indications

lung non-small cell carcinoma

Therapies

Binimetinib + Encorafenib

Age Groups: adult senior

Additional content available in CKB BOOST